Zymeworks Inc.

ZYME Healthcare Biotechnology

Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024. In the quarter to June 2026, revenue fell 90.6%, EPS fell 2,166.7% and free cash flow fell 385.5%, each against the same quarter a year earlier.

25.07 0.68 −2.64%
Market cap
$1.8B
P/E
0.0×
Fwd P/E
16.2×
Dividend yield
—
F-score
7/9
Altman Z
11.56
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
— 7 4 2 4 2 8 3 4 7
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 4.24 0.00 0.00 0.00
Altman Z-Score
— 5.95 3.79 6.83 9.64 0.07 2.90 2.15 2.59 11.56
P/S ratio
15.62 3.26 8.05 58.51 61.13 31.67 1.19 9.40 14.55 18.74
P/FCF ratio
0.00 0.00 20.57 0.00 0.00 0.00 3.75 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(1.28) 8.59 4.79 0.86 2.66 (3.93) 6.41 2.84 (1.97) (3.24)
Beneish M-Score
— (7.25) — — — — 2.12 — — —
P/Operating CF
(13.50) 4.32 8.52 (47.55) (49.71) (16.73) 1.50 51.23 (26.75) (193.53)
P/B ratio
0.00 1.45 2.37 7.04 5.81 3.39 1.00 1.54 3.28 7.39
Price to Tangible BV
0.00 1.63 2.56 7.59 6.06 3.62 1.04 1.61 3.45 7.78
EV/Sales
13.59 1.65 4.36 48.58 50.34 23.37 0.06 4.78 11.89 16.58
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00
EV/Operating CF
(3.64) 389.16 9.57 (17.53) (12.95) (3.24) 0.17 (3.07) (8.24) (53.23)
EV/FCF
(3.16) (29.37) 11.15 (14.61) (12.44) (3.03) 0.18 (2.89) (8.02) (49.69)
Quick Ratio
2.69 6.15 6.69 3.65 5.16 3.73 5.50 7.06 3.19 5.52
Current Ratio
2.81 6.30 6.82 3.78 5.31 4.01 5.70 7.41 3.40 5.88
Net Debt/EBITDA
0.97 14.03 6.73 2.08 2.41 1.23 (3.57) 3.10 1.79 2.81
Debt/Assets
4.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.19 0.46 0.28 0.10 0.09 0.06 0.79 0.12 0.15 0.26
Operating CF/Net income
1.04 (0.02) (0.66) 0.56 0.84 0.91 1.16 1.00 0.90 0.41
Capex/Depreciation
(5.33) (1.14) (0.94) (1.89) (0.61) (1.39) (1.81) (0.24) (0.27) (0.21)
Interest Coverage
(39.86) (21.32) (9.12) (25.12) (32.91) (109.74) 36.30 — — —
ROE
(248.22%) (17.42%) (24.62%) (68.25%) (55.08%) (64.29%) 33.51% (24.78%) (30.54%) (26.72%)
ROA
(57.72%) (9.67%) (19.42%) (47.48%) (39.83%) (45.68%) 23.96% (19.30%) (23.51%) (20.04%)
ROIC
(73.91%) (19.64%) 0.00% 0.00% 0.00% 0.00% 11,267.96% (95.36%) (75.84%) (145.69%)
Return on Tangible Assets
(92.25%) (12.88%) (20.21%) (60.50%) (47.32%) (88.58%) 26.24% (31.48%) (53.39%) (36.55%)
Average Days of Receivables
142.80 16.43 2.46 26.99 143.31 213.61 29.56 93.53 266.99 15.98
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
114.03% 35.84% 55.56% 217.23% 141.76% 159.52% 17.78% 92.68% 80.61% 58.05%
Intangible Assets out of Total Assets
0.14 0.10 0.06 0.05 0.03 0.04 0.03 0.03 0.04 0.04
Share Based Compensation of Revenue
38.98% 6.62% 25.35% 165.84% 74.75% 40.31% 0.97% 10.66% 23.32% 26.46%
Graham Net Nets
0.01 0.46 0.33 0.11 0.14 0.18 0.79 0.42 0.16 0.09
Graham Number
0.00 0.00 0.00 0.00 0.00 0.00 17.40 0.00 0.00 0.00
Earnings Yield
(27.92%) (14.00%) (9.20%) (8.10%) (7.58%) (25.08%) 23.61% (16.67%) (11.00%) (4.10%)
Free Cash Flow Yield
(27.58%) (1.72%) 4.86% (5.68%) (6.62%) (24.35%) 26.65% (17.59%) (10.19%) (1.78%)
Revenue per Share
0.86 2.44 1.82 0.78 0.77 0.52 6.33 1.10 1.01 1.41
Operating CF per Share
(2.77) 0.01 0.83 (2.15) (3.01) (3.73) 2.21 (1.72) (1.45) (0.44)
Capex per Share
(0.43) (0.15) (0.12) (0.36) (0.12) (0.26) (0.20) (0.06) (0.04) (0.03)
Free Cash Flow per Share
(3.20) (0.14) 0.71 (2.52) (3.13) (3.99) 2.01 (1.78) (1.49) (0.47)
Cash per Share
3.16 4.13 6.88 7.86 8.46 4.90 7.55 5.44 2.98 3.03
Shareholders Equity per Share
5.33 5.48 6.20 6.46 8.14 4.83 7.56 6.75 4.47 3.56
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
5.33 5.48 6.20 6.46 8.14 4.83 7.56 6.75 4.47 3.56
Free Cash Flow
(40.71) (2.90) 20.76 (95.73) (157.67) (205.74) 130.98 (122.38) (113.12) (35.36)
Working Capital
29.93 77.67 174.38 229.28 369.41 216.37 449.08 357.16 212.16 206.45
Capital Expenditures
(5.46) (3.12) (3.42) (13.88) (6.26) (13.28) (13.12) (4.08) (3.07) (2.35)
Net Current Asset Value
20.35 76.81 140.38 189.31 326.62 148.18 388.94 296.85 176.13 170.74
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.18 0.00 0.00 0.00
Capex to Sales
0.50 0.06 0.06 0.47 0.16 0.50 0.03 0.05 0.04 0.02
Price to Operating Income
0.00 0.00 0.00 0.00 0.00 0.00 3.77 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.15 0.38 0.56 0.66 0.84 0.42 0.29 0.87 0.63 0.72
Cash ROIC
(36.17%) (1.42%) 5.45% (17.58%) (18.85%) (41.01%) 13.30% (14.58%) (20.04%) (7.11%)
Accounts Receivable Turnover
3.35 15.60 39.45 23.24 4.46 1.73 16.83 2.88 2.03 3.51
Accounts Payable Turnover
5.16 4.51 5.07 4.72 4.32 3.75 2.78 2.15 2.54 2.85
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Days of Payables
93.96 79.15 85.94 112.40 93.07 114.73 153.05 116.89 162.24 96.83
Days of Inventory on Hand
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average Receivables
3.29 3.32 1.34 1.27 8.74 15.45 24.51 26.44 37.65 30.23
Average Payables
7.13 9.27 11.23 24.55 39.67 53.22 75.13 66.73 52.92 48.09
Average Assets
58.57 112.98 188.22 306.34 453.29 463.75 518.93 614.80 521.99 404.81
Average Common Equity
13.62 62.72 148.46 213.09 327.80 329.51 371.03 478.88 401.79 303.63

Fold the line items

Columns are period end dates